Moderately Macrosteatotic Livers Have Acceptable Long-Term Outcomes but Higher Risk of Immediate Mortality

• Published in: Transplantation proceedings Vol. 53; no. 5; pp. 1682 - 1689
• Main Authors: Alvikas, Jurgis, Deeb, Andrew-Paul, Jorgensen, Dana R., Minervini, Marta I, Demetris, Anthony J, Lemon, Kristina, Chen, Xilin, Labiner, Hanna, Malik, Shahid, Hughes, Christopher, Humar, Abhinav, Tevar, Amit
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2021
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2021.03.024

•Use of liver allografts with moderate macrosteatosis is controversial.•Uncertainty is in large part owing to heterogeneity is pretransplant biopsy assessment.•Outcomes of macrosteatotic livers graded at a single institution are reported.•Moderate macrosteatosis is a strong predictor of early mortality.•Patients who survive past 90 days can have acceptable long-term outcomes. Liver transplantation is the most effective treatment for end-stage liver disease (ESLD). Whether moderately macrosteatotic livers (30%-60%) represent a risk for worsened graft function is controversial. The uncertainty, in large part, is owing to the heterogeneous steatosis grading. Our aim was to determine the short- and long-term outcomes of moderately macrosteatotic allografts that were graded according to a standardized institutional protocol. We performed a retrospective analysis of transplants performed between 1994 and 2014. All patients with allografts biopsied pretransplantation were included. Relevant donor and recipient variable were recorded. Moderately macrosteatotic livers were compared with mildly macrosteatotic and nonsteatotic livers. Primary outcomes of interest were patient survival at 90 days, 1 year, and 5 years. Cox regression analyses were carried out to compare survival between the 2 groups. We compared 65 allografts with moderate macrosteatosis and 810 with no or mild macrosteatosis. Patients with moderately macrosteatotic allografts were 2.69 times as likely to die within the first 90 days after transplant (75.1% vs 91.6% survival) after adjusting for donor age, donor race, recipient age, recipient race, recipient body mass index, recipient diabetes, presence of hepatocellular carcinoma, days on waitlist, Model for End-Stage Liver Disease (MELD) score at transplantation, cold ischemia time. However, for recipients who survive 90 days, moderately macrosteatotic allografts had comparable long-term survival. Our study shows that moderate macrosteatosis is a strong predictor of early but not late mortality. Further studies are needed to distinguish the specific cohort of patients for whom moderately macrosteatotic allografts will lead to acceptable outcomes.